Global Kidney Disease Drugs Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Kidney Disease Drugs will have significant change from previous year. By the most conservative estimates of global Kidney Disease Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Kidney Disease Drugs market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Disease Drugs market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Kidney Disease Drugs, covering the supply chain analysis, impact assessment to the Kidney Disease Drugs market size growth rate in several scenarios, and the measures to be undertaken by Kidney Disease Drugs companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Tablets
Capsule
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Chronic Glomerulonephritis
Nephrotic Syndrome
Chronic Renal Failure
Kidney Stones
Renal Cyst (polycystic Kidney)
Diabetic Nephropathy
Hypertensive Nephropathy
Purpura Nephritis
Lupus Nephritis
Pediatric Kidney Disease
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
GlaxoSmithKline
Teva Pharmaceutical Industries
Sanofi
Pfizer
AstraZeneca
Roche
AbbVie
Keryx Biopharmaceuticals
Amgen
Kissei Pharmaceutical
zhejiang Shengbokang Pharmaceutical
Tianjin Tongrentang Group
Hebei Ruisen Pharmaceutical
Datong Liqun Pharmaceutical
Changxing Pharmaceutical
Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Kidney Disease Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Kidney Disease Drugs market by identifying its various subsegments.
Focuses on the key global Kidney Disease Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Kidney Disease Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Kidney Disease Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Kidney Disease Drugs?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Kidney Disease Drugs Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Kidney Disease Drugs Consumption 2015-2025
2.1.2 Kidney Disease Drugs Consumption CAGR by Region
2.2 Kidney Disease Drugs Segment by Type
2.2.1 Tablets
2.2.2 Capsule
2.2.3 Other
2.3 Kidney Disease Drugs Consumption by Type
2.3.1 Global Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Kidney Disease Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Kidney Disease Drugs Sale Price by Type (2015-2020)
2.4 Kidney Disease Drugs Segment by Application
2.4.1 Chronic Glomerulonephritis
2.4.2 Nephrotic Syndrome
2.4.3 Chronic Renal Failure
2.4.4 Kidney Stones
2.4.5 Renal Cyst (polycystic Kidney)
2.4.6 Diabetic Nephropathy
2.4.7 Hypertensive Nephropathy
2.4.8 Purpura Nephritis
2.4.9 Lupus Nephritis
2.4.10 Pediatric Kidney Disease
2.5 Kidney Disease Drugs Consumption by Application
2.5.1 Global Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Kidney Disease Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Kidney Disease Drugs Sale Price by Type (2015-2020)
3 Global Kidney Disease Drugs by Company
3.1 Global Kidney Disease Drugs Sales Market Share by Company
3.1.1 Global Kidney Disease Drugs Sales by Company (2018-2020)
3.1.2 Global Kidney Disease Drugs Sales Market Share by Company (2018-2020)
3.2 Global Kidney Disease Drugs Revenue Market Share by Company
3.2.1 Global Kidney Disease Drugs Revenue by Company (2018-2020)
3.2.2 Global Kidney Disease Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Kidney Disease Drugs Sale Price by Company
3.4 Global Kidney Disease Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Kidney Disease Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Kidney Disease Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Kidney Disease Drugs by Regions
4.1 Kidney Disease Drugs by Regions
4.2 Americas Kidney Disease Drugs Consumption Growth
4.3 APAC Kidney Disease Drugs Consumption Growth
4.4 Europe Kidney Disease Drugs Consumption Growth
4.5 Middle East & Africa Kidney Disease Drugs Consumption Growth
5 Americas
5.1 Americas Kidney Disease Drugs Consumption by Countries
5.1.1 Americas Kidney Disease Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Kidney Disease Drugs Value by Countries (2015-2020)
5.2 Americas Kidney Disease Drugs Consumption by Type
5.3 Americas Kidney Disease Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Kidney Disease Drugs Consumption by Regions
6.1.1 APAC Kidney Disease Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Kidney Disease Drugs Value by Regions (2015-2020)
6.2 APAC Kidney Disease Drugs Consumption by Type
6.3 APAC Kidney Disease Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Kidney Disease Drugs by Countries
7.1.1 Europe Kidney Disease Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Kidney Disease Drugs Value by Countries (2015-2020)
7.2 Europe Kidney Disease Drugs Consumption by Type
7.3 Europe Kidney Disease Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Kidney Disease Drugs by Countries
8.1.1 Middle East & Africa Kidney Disease Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Kidney Disease Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Kidney Disease Drugs Consumption by Type
8.3 Middle East & Africa Kidney Disease Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Kidney Disease Drugs Distributors
10.3 Kidney Disease Drugs Customer
11 Global Kidney Disease Drugs Market Forecast
11.1 Global Kidney Disease Drugs Consumption Forecast (2021-2025)
11.2 Global Kidney Disease Drugs Forecast by Regions
11.2.1 Global Kidney Disease Drugs Forecast by Regions (2021-2025)
11.2.2 Global Kidney Disease Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Kidney Disease Drugs Forecast by Type
11.8 Global Kidney Disease Drugs Forecast by Application
12 Key Players Analysis
12.1 GlaxoSmithKline
12.1.1 Company Information
12.1.2 Kidney Disease Drugs Product Offered
12.1.3 GlaxoSmithKline Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 GlaxoSmithKline Latest Developments
12.2 Teva Pharmaceutical Industries
12.2.1 Company Information
12.2.2 Kidney Disease Drugs Product Offered
12.2.3 Teva Pharmaceutical Industries Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Teva Pharmaceutical Industries Latest Developments
12.3 Sanofi
12.3.1 Company Information
12.3.2 Kidney Disease Drugs Product Offered
12.3.3 Sanofi Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Sanofi Latest Developments
12.4 Pfizer
12.4.1 Company Information
12.4.2 Kidney Disease Drugs Product Offered
12.4.3 Pfizer Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Pfizer Latest Developments
12.5 AstraZeneca
12.5.1 Company Information
12.5.2 Kidney Disease Drugs Product Offered
12.5.3 AstraZeneca Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 AstraZeneca Latest Developments
12.6 Roche
12.6.1 Company Information
12.6.2 Kidney Disease Drugs Product Offered
12.6.3 Roche Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Roche Latest Developments
12.7 AbbVie
12.7.1 Company Information
12.7.2 Kidney Disease Drugs Product Offered
12.7.3 AbbVie Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 AbbVie Latest Developments
12.8 Keryx Biopharmaceuticals
12.8.1 Company Information
12.8.2 Kidney Disease Drugs Product Offered
12.8.3 Keryx Biopharmaceuticals Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Keryx Biopharmaceuticals Latest Developments
12.9 Amgen
12.9.1 Company Information
12.9.2 Kidney Disease Drugs Product Offered
12.9.3 Amgen Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Amgen Latest Developments
12.10 Kissei Pharmaceutical
12.10.1 Company Information
12.10.2 Kidney Disease Drugs Product Offered
12.10.3 Kissei Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Kissei Pharmaceutical Latest Developments
12.11 zhejiang Shengbokang Pharmaceutical
12.11.1 Company Information
12.11.2 Kidney Disease Drugs Product Offered
12.11.3 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 zhejiang Shengbokang Pharmaceutical Latest Developments
12.12 Tianjin Tongrentang Group
12.12.1 Company Information
12.12.2 Kidney Disease Drugs Product Offered
12.12.3 Tianjin Tongrentang Group Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Tianjin Tongrentang Group Latest Developments
12.13 Hebei Ruisen Pharmaceutical
12.13.1 Company Information
12.13.2 Kidney Disease Drugs Product Offered
12.13.3 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Hebei Ruisen Pharmaceutical Latest Developments
12.14 Datong Liqun Pharmaceutical
12.14.1 Company Information
12.14.2 Kidney Disease Drugs Product Offered
12.14.3 Datong Liqun Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 Datong Liqun Pharmaceutical Latest Developments
12.15 Changxing Pharmaceutical
12.15.1 Company Information
12.15.2 Kidney Disease Drugs Product Offered
12.15.3 Changxing Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.15.4 Main Business Overview
12.15.5 Changxing Pharmaceutical Latest Developments
12.16 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
12.16.1 Company Information
12.16.2 Kidney Disease Drugs Product Offered
12.16.3 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.16.4 Main Business Overview
12.16.5 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Kidney Disease Drugs Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Kidney Disease Drugs Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Kidney Disease Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Tablets
Table 7. Major Players of Capsule
Table 8. Major Players of Other
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Table 11. Global Kidney Disease Drugs Revenue by Type (2015-2020) ($ million)
Table 12. Global Kidney Disease Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Kidney Disease Drugs Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Table 16. Global Kidney Disease Drugs Value by Application (2015-2020)
Table 17. Global Kidney Disease Drugs Value Market Share by Application (2015-2020)
Table 18. Global Kidney Disease Drugs Sale Price by Application (2015-2020)
Table 19. Global Kidney Disease Drugs Sales by Company (2017-2019) (K Units)
Table 20. Global Kidney Disease Drugs Sales Market Share by Company (2017-2019)
Table 21. Global Kidney Disease Drugs Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Kidney Disease Drugs Revenue Market Share by Company (2017-2019)
Table 23. Global Kidney Disease Drugs Sale Price by Company (2017-2019)
Table 24. Global Kidney Disease Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Kidney Disease Drugs Products Offered
Table 26. Kidney Disease Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Kidney Disease Drugs Consumption by Regions 2015-2020 (K Units)
Table 28. Global Kidney Disease Drugs Consumption Market Share by Regions 2015-2020
Table 29. Global Kidney Disease Drugs Value by Regions 2015-2020 ($ Millions)
Table 30. Global Kidney Disease Drugs Value Market Share by Regions 2015-2020
Table 31. Americas Kidney Disease Drugs Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Kidney Disease Drugs Consumption Market Share by Countries (2015-2020)
Table 33. Americas Kidney Disease Drugs Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Kidney Disease Drugs Value Market Share by Countries (2015-2020)
Table 35. Americas Kidney Disease Drugs Consumption by Type (2015-2020) (K Units)
Table 36. Americas Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Table 37. Americas Kidney Disease Drugs Consumption by Application (2015-2020) (K Units)
Table 38. Americas Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Table 39. APAC Kidney Disease Drugs Consumption by Countries (2015-2020) (K Units)
Table 40. APAC Kidney Disease Drugs Consumption Market Share by Countries (2015-2020)
Table 41. APAC Kidney Disease Drugs Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Kidney Disease Drugs Value Market Share by Regions (2015-2020)
Table 43. APAC Kidney Disease Drugs Consumption by Type (2015-2020) (K Units)
Table 44. APAC Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Table 45. APAC Kidney Disease Drugs Consumption by Application (2015-2020) (K Units)
Table 46. APAC Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Table 47. Europe Kidney Disease Drugs Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Kidney Disease Drugs Consumption Market Share by Countries (2015-2020)
Table 49. Europe Kidney Disease Drugs Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Kidney Disease Drugs Value Market Share by Countries (2015-2020)
Table 51. Europe Kidney Disease Drugs Consumption by Type (2015-2020) (K Units)
Table 52. Europe Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Table 53. Europe Kidney Disease Drugs Consumption by Application (2015-2020) (K Units)
Table 54. Europe Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Kidney Disease Drugs Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Kidney Disease Drugs Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Kidney Disease Drugs Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Kidney Disease Drugs Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Kidney Disease Drugs Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Table 63. Kidney Disease Drugs Distributors List
Table 64. Kidney Disease Drugs Customer List
Table 65. Global Kidney Disease Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Kidney Disease Drugs Consumption Market Forecast by Regions
Table 67. Global Kidney Disease Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Kidney Disease Drugs Value Market Share Forecast by Regions
Table 69. Global Kidney Disease Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Kidney Disease Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Kidney Disease Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Kidney Disease Drugs Value Market Share Forecast by Type (2021-2025)
Table 73. Global Kidney Disease Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Kidney Disease Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Kidney Disease Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Kidney Disease Drugs Value Market Share Forecast by Application (2021-2025)
Table 77. GlaxoSmithKline Product Offered
Table 78. GlaxoSmithKline Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 79. GlaxoSmithKline Main Business
Table 80. GlaxoSmithKline Latest Developments
Table 81. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Teva Pharmaceutical Industries Product Offered
Table 83. Teva Pharmaceutical Industries Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 84. Teva Pharmaceutical Industries Main Business
Table 85. Teva Pharmaceutical Industries Latest Developments
Table 86. Teva Pharmaceutical Industries Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Sanofi Product Offered
Table 88. Sanofi Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 89. Sanofi Main Business
Table 90. Sanofi Latest Developments
Table 91. Sanofi Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Pfizer Product Offered
Table 93. Pfizer Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 94. Pfizer Main Business
Table 95. Pfizer Latest Developments
Table 96. Pfizer Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. AstraZeneca Product Offered
Table 98. AstraZeneca Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 99. AstraZeneca Main Business
Table 100. AstraZeneca Latest Developments
Table 101. AstraZeneca Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Roche Product Offered
Table 103. Roche Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 104. Roche Main Business
Table 105. Roche Latest Developments
Table 106. Roche Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. AbbVie Product Offered
Table 108. AbbVie Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AbbVie Main Business
Table 110. AbbVie Latest Developments
Table 111. AbbVie Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Keryx Biopharmaceuticals Product Offered
Table 113. Keryx Biopharmaceuticals Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 114. Keryx Biopharmaceuticals Main Business
Table 115. Keryx Biopharmaceuticals Latest Developments
Table 116. Keryx Biopharmaceuticals Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Amgen Product Offered
Table 118. Amgen Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 119. Amgen Main Business
Table 120. Amgen Latest Developments
Table 121. Amgen Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Kissei Pharmaceutical Product Offered
Table 123. Kissei Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 124. Kissei Pharmaceutical Main Business
Table 125. Kissei Pharmaceutical Latest Developments
Table 126. Kissei Pharmaceutical Basic Information, Company Total Revenue (in $ million), Kidney Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. zhejiang Shengbokang Pharmaceutical Product Offered
Table 128. zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 129. zhejiang Shengbokang Pharmaceutical Main Business
Table 130. zhejiang Shengbokang Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 131. zhejiang Shengbokang Pharmaceutical Latest Developments
Table 132. Tianjin Tongrentang Group Product Offered
Table 133. Tianjin Tongrentang Group Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 134. Tianjin Tongrentang Group Main Business
Table 135. Tianjin Tongrentang Group Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 136. Tianjin Tongrentang Group Latest Developments
Table 137. Hebei Ruisen Pharmaceutical Product Offered
Table 138. Hebei Ruisen Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 139. Hebei Ruisen Pharmaceutical Main Business
Table 140. Hebei Ruisen Pharmaceutical Latest Developments
Table 141. Hebei Ruisen Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 142. Datong Liqun Pharmaceutical Product Offered
Table 143. Datong Liqun Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 144. Datong Liqun Pharmaceutical Main Business
Table 145. Datong Liqun Pharmaceutical Latest Developments
Table 146. Datong Liqun Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 147. Changxing Pharmaceutical Product Offered
Table 148. Changxing Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 149. Changxing Pharmaceutical Main Business
Table 150. Changxing Pharmaceutical Latest Developments
Table 151. Changxing Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 152. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Product Offered
Table 153. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 154. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Main Business
Table 155. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Latest Developments
Table 156. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Kidney Disease Drugs
Figure 2. Kidney Disease Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Kidney Disease Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Kidney Disease Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Tablets
Figure 7. Product Picture of Capsule
Figure 8. Product Picture of Other
Figure 9. Global Kidney Disease Drugs Consumption Market Share by Type (2015-2020)
Figure 10. Global Kidney Disease Drugs Value Market Share by Type (2015-2020)
Figure 11. Kidney Disease Drugs Consumed in Chronic Glomerulonephritis
Figure 12. Global Kidney Disease Drugs Market: Chronic Glomerulonephritis (2015-2020) (K Units)
Figure 13. Global Kidney Disease Drugs Market: Chronic Glomerulonephritis (2015-2020) ($ Millions)
Figure 14. Kidney Disease Drugs Consumed in Nephrotic Syndrome
Figure 15. Global Kidney Disease Drugs Market: Nephrotic Syndrome (2015-2020) (K Units)
Figure 16. Global Kidney Disease Drugs Market: Nephrotic Syndrome (2015-2020) ($ Millions)
Figure 17. Kidney Disease Drugs Consumed in Chronic Renal Failure
Figure 18. Global Kidney Disease Drugs Market: Chronic Renal Failure (2015-2020) (K Units)
Figure 19. Global Kidney Disease Drugs Market: Chronic Renal Failure (2015-2020) ($ Millions)
Figure 20. Kidney Disease Drugs Consumed in Kidney Stones
Figure 21. Global Kidney Disease Drugs Market: Kidney Stones (2015-2020) (K Units)
Figure 22. Global Kidney Disease Drugs Market: Kidney Stones (2015-2020) ($ Millions)
Figure 23. Kidney Disease Drugs Consumed in Renal Cyst (polycystic Kidney)
Figure 24. Global Kidney Disease Drugs Market: Renal Cyst (polycystic Kidney) (2015-2020) (K Units)
Figure 25. Global Kidney Disease Drugs Market: Renal Cyst (polycystic Kidney) (2015-2020) ($ Millions)
Figure 26. Kidney Disease Drugs Consumed in Diabetic Nephropathy
Figure 27. Kidney Disease Drugs Consumed in Hypertensive Nephropathy
Figure 28. Kidney Disease Drugs Consumed in Purpura Nephritis
Figure 29. Kidney Disease Drugs Consumed in Lupus Nephritis
Figure 30. Kidney Disease Drugs Consumed in Pediatric Kidney Disease
Figure 31. Global Kidney Disease Drugs Consumption Market Share by Application (2015-2020)
Figure 32. Global Kidney Disease Drugs Value Market Share by Application (2015-2020)
Figure 33. Global Kidney Disease Drugs Sales Market Share by Company in 2017
Figure 34. Global Kidney Disease Drugs Sales Market Share by Company in 2019
Figure 35. Global Kidney Disease Drugs Revenue Market Share by Company in 2017
Figure 36. Global Kidney Disease Drugs Revenue Market Share by Company in 2019
Figure 37. Global Kidney Disease Drugs Sale Price by Company in 2019
Figure 38. Global Kidney Disease Drugs Consumption Market Share by Regions 2015-2020
Figure 39. Global Kidney Disease Drugs Value Market Share by Regions 2015-2020
Figure 40. Americas Kidney Disease Drugs Consumption 2015-2020 (K Units)
Figure 41. Americas Kidney Disease Drugs Value 2015-2020 ($ Millions)
Figure 42. APAC Kidney Disease Drugs Consumption 2015-2020 (K Units)
Figure 43. APAC Kidney Disease Drugs Value 2015-2020 ($ Millions)
Figure 44. Europe Kidney Disease Drugs Consumption 2015-2020 (K Units)
Figure 45. Europe Kidney Disease Drugs Value 2015-2020 ($ Millions)
Figure 46. Middle East & Africa Kidney Disease Drugs Consumption 2015-2020 (K Units)
Figure 47. Middle East & Africa Kidney Disease Drugs Value 2015-2020 ($ Millions)
Figure 48. Americas Kidney Disease Drugs Consumption Market Share by Countries in 2019
Figure 49. Americas Kidney Disease Drugs Value Market Share by Countries in 2019
Figure 50. Americas Kidney Disease Drugs Consumption Market Share by Type in 2019
Figure 51. Americas Kidney Disease Drugs Consumption Market Share by Application in 2019
Figure 52. United States Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 53. United States Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 54. Canada Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. Canada Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Mexico Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Mexico Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. APAC Kidney Disease Drugs Consumption Market Share by Countries in 2019
Figure 59. APAC Kidney Disease Drugs Value Market Share by Regions in 2019
Figure 60. APAC Kidney Disease Drugs Consumption Market Share by Type in 2019
Figure 61. APAC Kidney Disease Drugs Consumption Market Share by Application in 2019
Figure 62. China Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 63. China Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Japan Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 65. Japan Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 66. Korea Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 67. Korea Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 68. Southeast Asia Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 69. Southeast Asia Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 70. India Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. India Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. Australia Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. Australia Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. Europe Kidney Disease Drugs Consumption Market Share by Countries in 2019
Figure 75. Europe Kidney Disease Drugs Value Market Share by Countries in 2019
Figure 76. Europe Kidney Disease Drugs Consumption Market Share by Type in 2019
Figure 77. Europe Kidney Disease Drugs Consumption Market Share by Application in 2019
Figure 78. Germany Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 79. Germany Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 80. France Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 81. France Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 82. UK Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 83. UK Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 84. Italy Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Italy Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. Russia Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. Russia Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Countries in 2019
Figure 89. Middle East & Africa Kidney Disease Drugs Value Market Share by Countries in 2019
Figure 90. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Type in 2019
Figure 91. Middle East & Africa Kidney Disease Drugs Consumption Market Share by Application in 2019
Figure 92. Egypt Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 93. Egypt Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 94. South Africa Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 95. South Africa Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 96. Israel Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 97. Israel Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 98. Turkey Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 99. Turkey Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 100. GCC Countries Kidney Disease Drugs Consumption Growth 2015-2020 (K Units)
Figure 101. GCC Countries Kidney Disease Drugs Value Growth 2015-2020 ($ Millions)
Figure 102. Global Kidney Disease Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 103. Global Kidney Disease Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 104. Americas Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 105. Americas Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 106. APAC Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 107. APAC Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 108. Europe Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 109. Europe Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 110. Middle East & Africa Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 111. Middle East & Africa Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 112. United States Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 113. United States Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 114. Canada Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 115. Canada Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 116. Mexico Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 117. Mexico Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 118. Brazil Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 119. Brazil Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 120. China Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 121. China Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 122. Japan Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 123. Japan Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 124. Korea Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 125. Korea Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 126. Southeast Asia Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 127. Southeast Asia Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 128. India Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 129. India Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 130. Australia Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 131. Australia Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 132. Germany Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 133. Germany Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 134. France Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 135. France Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 136. UK Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 137. UK Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 138. Italy Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 139. Italy Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 140. Russia Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 141. Russia Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 142. Spain Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 143. Spain Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 144. Egypt Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 145. Egypt Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 146. South Africa Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 147. South Africa Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 148. Israel Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 149. Israel Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 150. Turkey Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 151. Turkey Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 152. GCC Countries Kidney Disease Drugs Consumption 2021-2025 (K Units)
Figure 153. GCC Countries Kidney Disease Drugs Value 2021-2025 ($ Millions)
Figure 154. GlaxoSmithKline Kidney Disease Drugs Market Share (2018-2020)
Figure 155. Teva Pharmaceutical Industries Kidney Disease Drugs Market Share (2018-2020)
Figure 156. Sanofi Kidney Disease Drugs Market Share (2018-2020)
Figure 157. Pfizer Kidney Disease Drugs Market Share (2018-2020)
Figure 158. AstraZeneca Kidney Disease Drugs Market Share (2018-2020)
Figure 159. Roche Kidney Disease Drugs Market Share (2018-2020)
Figure 160. AbbVie Kidney Disease Drugs Market Share (2018-2020)
Figure 161. Keryx Biopharmaceuticals Kidney Disease Drugs Market Share (2018-2020)
Figure 162. Amgen Kidney Disease Drugs Market Share (2018-2020)
Figure 163. Kissei Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Figure 164. zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Figure 165. Tianjin Tongrentang Group Kidney Disease Drugs Market Share (2018-2020)
Figure 166. Hebei Ruisen Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Figure 167. Datong Liqun Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Figure 168. Changxing Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Figure 169. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets